Replies to post #86881 on Biotech Values

[DewDiligence]

Re: TriCor litigation

I thought Teva would launch at-risk on July 2010. Either the market looks too small for the risk or ABT gave them something in return to the 8 months delay [until Mar 2011]

By 2H10, the conversion from TriCor to TriLipix/Certriad* should be pretty far along, so what Teva saved in legal expenses by settling the case probably justifies their waiting eight months to launch generic TriCor. I highly doubt that ABT offered Teva a direct monetary inducement to settle—such a provision would almost certainly backfire.

*Certriad PDUFA date is in Apr 2010.